2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

Alexander R. Lyon; Teresa López-Fernández; ESC Scientific Document Group; Oskars Kalejs

doi:10.1093/eurheartj/ehac244

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

Alexander R. Lyon (Corresponding Author)
, Teresa López-Fernández (Corresponding Author)
, ESC Scientific Document Group
, Oskars Kalejs (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

2230 Citations (Scopus)

Original language	English
Pages (from-to)	4229-4361
Number of pages	133
Journal	European Heart Journal
Volume	43
Issue number	41
DOIs	https://doi.org/10.1093/eurheartj/ehac244
Publication status	Published - Nov 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords*

Amyloid light-chain cardiac amyloidosis
Androgen deprivation therapy
Anthracycline
Arrhythmias
Atrial fibrillation
Biomarkers
Cancer
Cancer survivors
Carcinoid syndrome
Cardiac magnetic resonance
Cardiac tumour
Cardio-oncology
Cardiotoxicity
Chemotherapy
Coronary artery disease
Echocardiography
Fluoropyrimidine
Guidelines
Haematopoietic stem cell transplantation
Heart failure
Hormone therapy
Hypertension
Immunotherapy
Ischaemic heart disease
Myocarditis
Pericardial disease
Proteasome inhibitors
Pulmonary hypertension
QTc prolongation
Radiotherapy
Risk stratification
Strain
Thrombosis
Trastuzumab
Valvular heart disease
Vascular endothelial growth factor inhibitors (VEGFi)
Venous thromboembolism

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1093/eurheartj/ehac244

Cite this

Lyon, A. R., López-Fernández, T., ESC Scientific Document Group, & Kalejs, O. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal, 43(41), 4229-4361. https://doi.org/10.1093/eurheartj/ehac244

Lyon, Alexander R. ; López-Fernández, Teresa ; ESC Scientific Document Group et al. / 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) : Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). In: European Heart Journal. 2022 ; Vol. 43, No. 41. pp. 4229-4361.

@article{8316edde87fb4fb9877ffad1dfff8165,

title = "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)",

keywords = "Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Anthracycline, Arrhythmias, Atrial fibrillation, Biomarkers, Cancer, Cancer survivors, Carcinoid syndrome, Cardiac magnetic resonance, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Coronary artery disease, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Strain, Thrombosis, Trastuzumab, Valvular heart disease, Vascular endothelial growth factor inhibitors (VEGFi), Venous thromboembolism",

author = "Lyon, \{Alexander R.\} and Teresa L{\'o}pez-Fern{\'a}ndez and \{ESC Scientific Document Group\} and Couch, \{Liam S.\} and Riccardo Asteggiano and Aznar, \{Marianne C.\} and Jutta Bergler-Klein and Giuseppe Boriani and Daniela Cardinale and Raul Cordoba and Bernard Cosyns and Cutter, \{David J.\} and \{de Azambuja\}, Evandro and \{de Boer\}, \{Rudolf A.\} and Dent, \{Susan F.\} and Dimitrios Farmakis and Gevaert, \{Sofie A.\} and Gorog, \{Diana A.\} and Joerg Herrmann and Daniel Lenihan and Javid Moslehi and Richard Stephens and Sebastian Szmit and Juan Tamargo and Paaladinesh Thavendiranathan and Tocchetti, \{Carlo G.\} and \{van der Meer\}, Peter and \{van der Pal\}, \{Helena J.H.\} and Patrizio Lancellotti and Franck Thuny and Magdy Abdelhamid and Berthe Aleman and Borger, \{Michael A.\} and Ruben Casado-Arroyo and Jennifer Cautela and Alain Cohen-Solal and St{\'e}phane Ederhy and Michael Fradley and Julia Grapsa and Sigrun Halvorsen and Oskars Kalejs",

year = "2022",

month = nov,

doi = "10.1093/eurheartj/ehac244",

language = "English",

volume = "43",

pages = "4229--4361",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "41",

}

Lyon, AR, López-Fernández, T, ESC Scientific Document Group & Kalejs, O 2022, '2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)', European Heart Journal, vol. 43, no. 41, pp. 4229-4361. https://doi.org/10.1093/eurheartj/ehac244

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). / Lyon, Alexander R. (Corresponding Author); López-Fernández, Teresa (Corresponding Author); ESC Scientific Document Group et al.
In: European Heart Journal, Vol. 43, No. 41, 11.2022, p. 4229-4361.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

T2 - Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

AU - Lyon, Alexander R.

AU - López-Fernández, Teresa

AU - ESC Scientific Document Group

A2 - Couch, Liam S.

A2 - Asteggiano, Riccardo

A2 - Aznar, Marianne C.

A2 - Bergler-Klein, Jutta

A2 - Boriani, Giuseppe

A2 - Cardinale, Daniela

A2 - Cordoba, Raul

A2 - Cosyns, Bernard

A2 - Cutter, David J.

A2 - de Azambuja, Evandro

A2 - de Boer, Rudolf A.

A2 - Dent, Susan F.

A2 - Farmakis, Dimitrios

A2 - Gevaert, Sofie A.

A2 - Gorog, Diana A.

A2 - Herrmann, Joerg

A2 - Lenihan, Daniel

A2 - Moslehi, Javid

A2 - Stephens, Richard

A2 - Szmit, Sebastian

A2 - Tamargo, Juan

A2 - Thavendiranathan, Paaladinesh

A2 - Tocchetti, Carlo G.

A2 - van der Meer, Peter

A2 - van der Pal, Helena J.H.

A2 - Lancellotti, Patrizio

A2 - Thuny, Franck

A2 - Abdelhamid, Magdy

A2 - Aleman, Berthe

A2 - Borger, Michael A.

A2 - Casado-Arroyo, Ruben

A2 - Cautela, Jennifer

A2 - Cohen-Solal, Alain

A2 - Ederhy, Stéphane

A2 - Fradley, Michael

A2 - Grapsa, Julia

A2 - Halvorsen, Sigrun

A2 - Kalejs, Oskars

PY - 2022/11

Y1 - 2022/11

KW - Amyloid light-chain cardiac amyloidosis

KW - Androgen deprivation therapy

KW - Anthracycline

KW - Arrhythmias

KW - Atrial fibrillation

KW - Biomarkers

KW - Cancer

KW - Cancer survivors

KW - Carcinoid syndrome

KW - Cardiac magnetic resonance

KW - Cardiac tumour

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Chemotherapy

KW - Coronary artery disease

KW - Echocardiography

KW - Fluoropyrimidine

KW - Guidelines

KW - Haematopoietic stem cell transplantation

KW - Heart failure

KW - Hormone therapy

KW - Hypertension

KW - Immunotherapy

KW - Ischaemic heart disease

KW - Myocarditis

KW - Pericardial disease

KW - Proteasome inhibitors

KW - Pulmonary hypertension

KW - QTc prolongation

KW - Radiotherapy

KW - Risk stratification

KW - Strain

KW - Thrombosis

KW - Trastuzumab

KW - Valvular heart disease

KW - Vascular endothelial growth factor inhibitors (VEGFi)

KW - Venous thromboembolism

UR - https://www.scopus.com/pages/publications/85139297152

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000849692300001

U2 - 10.1093/eurheartj/ehac244

DO - 10.1093/eurheartj/ehac244

M3 - Article

C2 - 36017568

AN - SCOPUS:85139297152

SN - 0195-668X

VL - 43

SP - 4229

EP - 4361

JO - European Heart Journal

JF - European Heart Journal

IS - 41

ER -